DEK oncoprotein participates in heterochromatin replication via SUMO-dependent nuclear bodies.
Agnieszka Pierzynska-MachChristina CzadaChristopher VogelEva GwoschXenia OsswaldDenis BartoschekAlberto DiasproFerdinand KappesElisa Ferrando-MayPublished in: Journal of cell science (2023)
The correct inheritance of chromatin structure is key for maintaining genome function and cell identity and preventing cellular transformation. DEK, a conserved non-histone chromatin protein, has recognized tumor-promoting properties, its overexpression being associated with poor prognosis in various cancer types. At the cellular level, DEK displays pleiotropic functions, influencing differentiation, apoptosis, and stemness, but a characteristic oncogenic mechanism has remained elusive. Here we report the identification of DEK bodies, focal assemblies of DEK regularly occurring at specific, yet unidentified sites of heterochromatin replication exclusively in late S-phase. In these bodies, DEK localizes in direct proximity to active replisomes in agreement with a function in the early maturation of heterochromatin. A high-throughput siRNA screen, supported by mutational and biochemical analyses, identifies SUMO as one regulator of DEK body formation, linking DEK to the complex SUMO protein network that controls chromatin states and cell fate. This work combines and refines our previous data on DEK as a factor essential for heterochromatin integrity and facilitating replication under stress and delineates an avenue of further study for unraveling DEK´s contribution to cancer development.
Keyphrases
- transcription factor
- poor prognosis
- high throughput
- genome wide
- dna damage
- gene expression
- long non coding rna
- papillary thyroid
- dna methylation
- stem cells
- squamous cell carcinoma
- single cell
- oxidative stress
- cell fate
- cell death
- drug delivery
- signaling pathway
- protein protein
- machine learning
- epithelial mesenchymal transition
- mesenchymal stem cells
- squamous cell
- amino acid
- big data
- mitochondrial dna
- young adults
- electronic health record
- cell cycle arrest
- cancer therapy